2種の母集団薬物動態パラメータを用いたテイコプラニン血清中トラフ濃度の予測性
スポンサーリンク
概要
- 論文の詳細を見る
The Teicoplanin TDM analysis software provided by Astellas Pharma Inc. was updated to Ver.2.0 and we tested it in comparison with Ver.1.0 to determine whether its predictions based on population pharmacokinetic parameters were useful in the design of initial and maintenance regimens. In addition, since renal function may be overestimated when the serum creatinine concentration is low, we determined whether correction of serum creatinine concentrations improved predictive capability with respect to initial regimens. As regards predictive performance, for initial regimens, the mean prediction error (ME) for Ver.1.0 was greater than zero and the 95% confidence interval did not include zero. These results indicate that concentrations predicted using Ver. 1.0 would be significantly higher than the observed concentrations. The ME for Ver.2.0 was smaller and the 95% confidence interval included zero indicating that its predictive performance was superior to that of Ver. 1.0. However, the correction of serum creatinine concentrations did not improve predictive performance for initial regimens. Using the Bayesian method, no significant correlation was observed between the observed and predicted concentrations for maintenance regimens for either Ver.1.0 or Ver.2.0 due to the small patient population used. With respect to observed concentrations at blood sampling times from 48 to 72 h from the start of administration, the predictive capabilities of both Ver. 1.0 and Ver.2.0 were good. The results of this study indicated that for initial regimens, the method used for Ver.2.0 would be more useful, though the correction of serum creatinine concentrations did not improve predictive performance in this case.
- 日本医療薬学会の論文
- 2007-08-10
著者
関連論文
- 21-P2-270 Oxaliplatinが原因と考えられるアレルギー反応への対策と検討(がん薬物療法(副作用対策),来るべき時代への道を拓く)
- 21-P2-241 化学療法レジメンオーダーシステム導入前後での抗がん剤調製業務における疑義照会の調査(がん薬物療法(リスクマネジメント),来るべき時代への道を拓く)
- 20. 小児の家庭における服薬上の問題への取り組み(第14回日本小児外科QOL研究会)
- O-36 硫酸アルベカシン初回投与設計方法の検討
- 29. 10カ月時に生体肝移植を余儀なくされた胆道閉鎖症術後難治性胆管炎の1例(第31回胆道閉鎖症研究会)
- P2-239 腎機能に応じたテイコプラニンの初期負荷投与設計(一般演題 ポスター発表,薬物動態・TDM・投与設計,臨床から学び臨床へと還元する医療薬学)
- P2-250 抗MRSA用薬剤血中濃度解析ソフトの作成(一般演題 ポスター発表,薬物動態(臨床、TDM),医療薬学の創る未来 科学と臨床の融合)
- 21-P3-474 テイコプラニン初期負荷投与方法の検討(TDM・投与設計,来るべき時代への道を拓く)
- 21-P3-473 抗MRSA用薬剤初期投与設計ソフトの作成(TDM・投与設計,来るべき時代への道を拓く)
- 異なるバンコマイシンパラメータ間における血中濃度予測の検討